Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Raises $13M in Series B Round

NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.

Proceeds will go toward expanding the San Diego-based firm's R&D operations and capabilities to commercialize its platform for the molecular characterization of circulating tumor cells in blood. The technology is licensed from Peter Kuhn's laboratory at The Scripps Research Institute.

Epic currently has collaborations with seven pharmaceutical firms to develop companion diagnostics for oncology drug candidates, it said, including a number of partnerships in Phase I and II clinical trials.

The Series B round includes new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as unnamed individual investors. Kim Kamdar, a partner in Domain, is joining Epic's board in conjunction with the financing, Epic said.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.